WONDFO BIOTECH(SZ:300482)2022-12-06 11:16Group 1: Company Strategy and Market Position - The company focuses on three main areas: cardiovascular diseases, respiratory diseases, and infectious diseases, with the reproductive health sector being of lower strategic importance due to its limited market capacity [2]. - The company has been promoting its reproductive health products through e-commerce and various distributors, indicating future growth potential in this sector [2]. Group 2: Financial Performance and Growth - The company maintained a net profit growth rate of over 20% in the current year, despite a slowdown in growth over the past two years [3]. - The company invests over 10% of its revenue in research and development annually [3]. Group 3: Product Development and Innovation - The company has the only domestic product for sperm motility testing, which provides a competitive edge over other POCT industry companies [3]. - New products are expected to be launched annually, with a three-year planning cycle for product development [3]. Group 4: Sales and Marketing Strategy - The sales model is based on a distributor approach, with a goal of globalizing the business across R&D, production, and sales [4]. - Recent CE certifications for products related to myocardial infarction and heart failure are expected to enhance sales in Europe and the United States [4]. Group 5: Mergers and Acquisitions - The company aims to pursue technology-driven mergers and acquisitions to enhance its product line and production capabilities [4]. - The company has a stable history of operations and plans to maintain a cautious approach in investment activities [4]. Group 6: Government Support and Financial Impact - Government subsidies have remained stable at around 20 million, primarily supporting high-tech enterprises and biopharmaceutical research [4]. - As the company grows, the proportion of government subsidies to net profit is expected to decrease, indicating a reduced reliance on such support [4].